PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 67% · Mixed 24% · Unfavorable overall 9%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.01–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 15 days · Based on 491 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 47% · Mixed 34% · Unfavorable overall 19%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 295 repeat reporters
Published sources linked on the KLOW Blend and Larazotide wiki pages.
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
Review Article
Pickart L, Margolina A. Cosmetics. 2018
PubMed
Luger TA, Brzoska T. Ann N Y Acad Sci. 2004
PubMed
Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015
PubMed
Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026
PubMed
Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016